What is the argument against AHZ splitting into two companies: one that focuses on developing and selling world-class Medtech and the other that focuses on curing cancer and wiping out Herpes?
I find it bizarre that AHZ is doing both: on one hand it makes profits from at least one of its medtech products, and on the other, it feeds the money-sucking biotech-hopeful side of the business.
this could be a case of where 1 + 1 = 1 and a half
split them into two and it could be 1 + 1 = 3
What is the argument against AHZ splitting into two companies:...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |